Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Helus Pharma (HELP) announced updates on its mental health drug programs. HLP003 Phase 3 data readout is on track for Q4 2026, with FDA Breakthrough Therapy Designation. HLP004 Phase 2 monotherapy study for GAD is expected to start in Q1 2027, enrolling 144 adults. The company aims for FDA filing in 2028.

Novavax (NVAX) fell 12% to $11.23, Moderna (MRNA) dropped 10% to $212.80, while Pfizer (PFE) rose 0.5% to $29.59. Citi maintained a Sell rating on NVAX but raised its price target. NVAX's revenue depends on Sanofi's (SNY) Nuvaxovid sales and milestones, creating uncertainty.

Novavax (NVAX) stock fell 10.5% to $11.475 after Citigroup reiterated a Sell rating with a $8 price target, 38% below its 52-week high. High short interest and a bearish note from Bank of America also contributed to the decline. The broader market's negative tone added to the pressure.

Ultragenyx sold a rare pediatric PRV for $203M, its second such sale in a week. The voucher was earned after FDA approval of FAYUVI for MPS IIIA. The buyer is undisclosed. The deal follows a $210M sale of another PRV, totaling $413M. The company plans to use the funds for R&D and profitability.

Ultragenyx Pharmaceutical (RARE) sold a $203M priority review voucher tied to its gene therapy Fayuvi's FDA approval, marking its second such sale this month. The company's P/S ratio is 2.1, below its historical median of 15.7, reflecting market skepticism. Its GF Score™ is 48/100, indicating mixed financial health. Insiders have sold $3.7M in shares over the past year.

Ultragenyx Pharmaceutical announced it will sell a rare pediatric disease priority review voucher for $203 million, following FDA approval of its treatment for mucopolysaccharidosis type IIIA. The deal is pending customary closing conditions, including antitrust review.